Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bronchial Thermoplasty in Severe Persistent Asthma

Study:

Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma

Rationale:

n/a

Purpose:

As Conditions of Approval of the PMA for the Alair System, the FDA requires Asthmatx to generate data to assess the durability of the BT treatment effect as well as safety data in the intended use population in the United States.

Study Status: Recruiting

Recruiting:
Joanne Baran-Smiley, RN, BSN 216-444-5023 baranj2@ccf.org

Condition Intervention Phase
Severe Asthma Device: Alair System Phase 4

Verified by Asthmatx, Inc. January, 2014

Sponsored by: Asthmatx, Inc.
Information provided by: Asthmatx, Inc.
ClinicalTrials.gov identifier: NCT01350336

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site